| 2017-05-17 06:37:35 | Alnylam price target raised to $80 from $75 at LadenburgLadenburg Thalmann analyst Christopher James raised his price target for Alnylam (ALNY) to $80 saying the NEURO-TTR data reported by Ionis Pharmaceuticals (IONS) are "quite positive" for patisiran and the upcoming APOLLO readout. The analyst reiterates a Buy rating on Alnylam shares. | |
|---|---|---|
| | ||
| , |
| |
|---|---|---|
| , |
| |
| ||
| | |
| , … |
|
| , |
| |
|---|---|---|
| | |
| , … |
| |
| | |
| |
| ||
| | |
| | |
| , |
| |
|
| ||
| ||
| | |
| ||
|
| ||
| | |
| ||
| | |
|